Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 1999 Nov;45:2626-8, 2630-3.

Valsartan. Just a second-line antihypertensive drug.

PMCID: PMC2328654  PMID: 10587770

Abstract

Valsartan (Diovan) is an antihypertensive drug belonging to the family of angiotensin II receptor antagonists. At a dose of 40 mg/d, its antihypertensive effect is inconsistent. At 80 mg/d its effect on blood pressure, its adverse effects, and its contraindications (mainly pregnancy and renal artery stenosis) are similar to those of angiotensin-converting enzyme (ACE) inhibitors, except that coughing is rarer with valsartan than with ACE inhibitors. Valsartan has no demonstrated advantage over losartan, another angiotensin II antagonist. Valsartan has not been shown to prevent complications of arterial hypertension, and its use is, therefore, less well validated than that of diuretics and beta-blockers.

Full text

PDF
2626

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benz J., Oshrain C., Henry D., Avery C., Chiang Y. T., Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997 Feb;37(2):101–107. doi: 10.1002/j.1552-4604.1997.tb04767.x. [DOI] [PubMed] [Google Scholar]
  2. Benz J., Oshrain C., Henry D., Avery C., Chiang Y. T., Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997 Feb;37(2):101–107. doi: 10.1002/j.1552-4604.1997.tb04767.x. [DOI] [PubMed] [Google Scholar]
  3. Bremner A. D., Baur M., Oddou-Stock P., Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens. 1997 Nov;19(8):1263–1285. doi: 10.3109/10641969709083217. [DOI] [PubMed] [Google Scholar]
  4. Bremner A. D., Baur M., Oddou-Stock P., Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens. 1997 Nov;19(8):1263–1285. doi: 10.3109/10641969709083217. [DOI] [PubMed] [Google Scholar]
  5. Corea L., Cardoni O., Fogari R., Innocenti P., Porcellati C., Provvidenza M., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996 Sep;60(3):341–346. doi: 10.1016/S0009-9236(96)90061-2. [DOI] [PubMed] [Google Scholar]
  6. Corea L., Cardoni O., Fogari R., Innocenti P., Porcellati C., Provvidenza M., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996 Sep;60(3):341–346. doi: 10.1016/S0009-9236(96)90061-2. [DOI] [PubMed] [Google Scholar]
  7. Fortuño A., Tisaire J., López R., Bueno J., Díez J. Angiotensin converting enzyme inhibition corrects Na+/H+ exchanger overactivity in essential hypertension. Am J Hypertens. 1997 Jan;10(1):84–93. doi: 10.1016/s0895-7061(96)00296-8. [DOI] [PubMed] [Google Scholar]
  8. Fortuño A., Tisaire J., López R., Bueno J., Díez J. Angiotensin converting enzyme inhibition corrects Na+/H+ exchanger overactivity in essential hypertension. Am J Hypertens. 1997 Jan;10(1):84–93. doi: 10.1016/s0895-7061(96)00296-8. [DOI] [PubMed] [Google Scholar]
  9. Hegner G., Faust G., Freytag F., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol. 1997;52(3):173–177. doi: 10.1007/s002280050270. [DOI] [PubMed] [Google Scholar]
  10. Hegner G., Faust G., Freytag F., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol. 1997;52(3):173–177. doi: 10.1007/s002280050270. [DOI] [PubMed] [Google Scholar]
  11. Holwerda N. J., Fogari R., Angeli P., Porcellati C., Hereng C., Oddou-Stock P., Heath R., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996 Sep;14(9):1147–1151. doi: 10.1097/00004872-199609000-00016. [DOI] [PubMed] [Google Scholar]
  12. Holwerda N. J., Fogari R., Angeli P., Porcellati C., Hereng C., Oddou-Stock P., Heath R., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996 Sep;14(9):1147–1151. doi: 10.1097/00004872-199609000-00016. [DOI] [PubMed] [Google Scholar]
  13. Markham A., Goa K. L. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997 Aug;54(2):299–311. doi: 10.2165/00003495-199754020-00009. [DOI] [PubMed] [Google Scholar]
  14. Markham A., Goa K. L. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997 Aug;54(2):299–311. doi: 10.2165/00003495-199754020-00009. [DOI] [PubMed] [Google Scholar]
  15. Oparil S., Dyke S., Harris F., Kief J., James D., Hester A., Fitzsimmons S. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996 Sep-Oct;18(5):797–810. doi: 10.1016/s0149-2918(96)80040-3. [DOI] [PubMed] [Google Scholar]
  16. Oparil S., Dyke S., Harris F., Kief J., James D., Hester A., Fitzsimmons S. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996 Sep-Oct;18(5):797–810. doi: 10.1016/s0149-2918(96)80040-3. [DOI] [PubMed] [Google Scholar]
  17. Pitt B., Segal R., Martinez F. A., Meurers G., Cowley A. J., Thomas I., Deedwania P. C., Ney D. E., Snavely D. B., Chang P. I. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet. 1997 Mar 15;349(9054):747–752. doi: 10.1016/s0140-6736(97)01187-2. [DOI] [PubMed] [Google Scholar]
  18. Pitt B., Segal R., Martinez F. A., Meurers G., Cowley A. J., Thomas I., Deedwania P. C., Ney D. E., Snavely D. B., Chang P. I. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet. 1997 Mar 15;349(9054):747–752. doi: 10.1016/s0140-6736(97)01187-2. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES